Literature DB >> 23033144

An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice.

Vandana Kaul1, Debapriya Bhattacharya, Yogesh Singh, Luc Van Kaer, Marc Peters-Golden, William R Bishai, Gobardhan Das.   

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis, resides and replicates within susceptible hosts by inhibiting host antimicrobial mechanisms. Prostaglandin E(2) (PGE(2)), produced by M. tuberculosis-infected macrophages, exerts a variety of immunomodulatory functions via 4 receptors (EP1-EP4), each mediating distinct PGE(2) functions. Here, we show that M. tuberculosis infection selectively upregulates EP2 messenger RNA expression in CD4(+) T cells. We found that EP2 deficiency in mice increases susceptibility to M. tuberculosis infection, which correlated with reduced antigen-specific T-cell responses and increased levels of CD4(+)CD25(+)Foxp3(+) T-regulatory cells. These findings have revealed an important role for EP2 in host immune defense against tuberculosis. As a G protein-coupled receptor, EP2 could serve as a target for immunotherapy of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23033144      PMCID: PMC3502376          DOI: 10.1093/infdis/jis609

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 2.  The pathogenesis of tuberculosis.

Authors:  G A Rook; R Hernandez-Pando
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

3.  Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor.

Authors:  C R Kennedy; Y Zhang; S Brandon; Y Guan; K Coffee; C D Funk; M A Magnuson; J A Oates; M D Breyer; R M Breyer
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172).

Authors:  D Dlugovitzky; O Bottasso; J C Dominino; E Valentini; R Hartopp; M Singh; C Stanford; J Stanford
Journal:  Respir Med       Date:  1999-08       Impact factor: 3.415

5.  Expression of transforming growth factor-beta but not tumor necrosis factor-alpha, interferon-gamma, and interleukin-4 in granulomatous lung lesions in tuberculosis.

Authors:  H Aung; Z Toossi; S M McKenna; P Gogate; J Sierra; E Sada; E A Rich
Journal:  Tuber Lung Dis       Date:  2000

6.  The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis.

Authors:  Javier Rangel Moreno; Iris Estrada García; María De La Luz García Hernández; Diana Aguilar Leon; Ricardo Marquez; Rogelio Hernández Pando
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

7.  Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse.

Authors:  C Nataraj; D W Thomas; S L Tilley; M T Nguyen; R Mannon; B H Koller; T M Coffman
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

8.  Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes.

Authors:  Hedi Harizi; Christophe Grosset; Norbert Gualde
Journal:  J Leukoc Biol       Date:  2003-06       Impact factor: 4.962

9.  PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.

Authors:  Maozhen Tian; William P Schiemann
Journal:  FASEB J       Date:  2009-11-06       Impact factor: 5.191

10.  E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization.

Authors:  Shinichiro Kubo; Hideo Kohka Takahashi; Masao Takei; Hiromi Iwagaki; Tadashi Yoshino; Noriaki Tanaka; Shuji Mori; Masahiro Nishibori
Journal:  J Pharmacol Exp Ther       Date:  2004-02-10       Impact factor: 4.030

View more
  13 in total

1.  Eicosanoids, prostaglandins, and the progression of tuberculosis.

Authors:  Deepak Kaushal
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

Review 2.  Prostaglandin E2 as a Regulator of Immunity to Pathogens.

Authors:  Giovanny J Martínez-Colón; Bethany B Moore
Journal:  Pharmacol Ther       Date:  2017-12-22       Impact factor: 12.310

Review 3.  Cytokine and lipid mediator networks in tuberculosis.

Authors:  Katrin D Mayer-Barber; Alan Sher
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

Review 4.  Macrophage: A Cell With Many Faces and Functions in Tuberculosis.

Authors:  Faraz Ahmad; Anshu Rani; Anwar Alam; Sheeba Zarin; Saurabh Pandey; Hina Singh; Seyed Ehtesham Hasnain; Nasreen Zafar Ehtesham
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

5.  Sex-Dependent Differential Expression of Lipidic Mediators Associated with Inflammation Resolution in Patients with Pulmonary Tuberculosis.

Authors:  Claudia Carranza; Laura Elena Carreto-Binaghi; Silvia Guzmán-Beltrán; Marcela Muñoz-Torrico; Martha Torres; Yolanda González; Esmeralda Juárez
Journal:  Biomolecules       Date:  2022-03-24

Review 6.  Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop.

Authors:  Jillian Dietzold; Archana Gopalakrishnan; Padmini Salgame
Journal:  F1000Prime Rep       Date:  2015-03-03

Review 7.  Alveolar lipids in pulmonary disease. A review.

Authors:  Christina W Agudelo; Ghassan Samaha; Itsaso Garcia-Arcos
Journal:  Lipids Health Dis       Date:  2020-06-03       Impact factor: 3.876

8.  Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease.

Authors:  Kristin Grotle Nore; Marthe Jøntvedt Jørgensen; Anne Ma Dyrhol-Riise; Synne Jenum; Kristian Tonby
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

9.  Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.

Authors:  Marthe Jøntvedt Jørgensen; Kristin G Nore; Hans Christian D Aass; Emilie Layre; Jérôme Nigou; Rasmus Mortensen; Kjetil Tasken; Dag Kvale; Synne Jenum; Kristian Tonby; Anne Ma Dyrhol-Riise
Journal:  Front Cell Infect Microbiol       Date:  2021-07-09       Impact factor: 5.293

10.  Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis.

Authors:  Neharika Jain; Haroon Kalam; Lakshyaveer Singh; Vartika Sharma; Saurabh Kedia; Prasenjit Das; Vineet Ahuja; Dhiraj Kumar
Journal:  Nat Commun       Date:  2020-06-16       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.